CO 065: WHY AND FOR WHAT CREATING A LATINAMERICAN-IBEROAMERICAN NETWORK FOR ALTERNATIVES?

J Pharm Pharmacogn Res 2(Suppl. 1): S39, 2014

Special supplement with the abstract book of LATINFARMA 2013

Oral Communication

CO 065: WHY AND FOR WHAT CREATING A LATINAMERICAN-IBEROAMERICAN NETWORK FOR ALTERNATIVES?

Chovel ML.

Instituto Finlay, La Habana, Cuba.
Abstract

To the light of the new approaches and trends, as well as considering the progress reached in the development, validation and the implementation of technologies and methods based on the principle of 3Rs worldwide, it is absolutely necessary to create a framework able to integrate the groups working on alternatives in Latin-America. Thus, it will be possible to reinforce our strengths and to overcome our weaknesses by means of the experience exchange and the scientific collaboration, courses and trainings, participation in proficiency and interlaboratory validation studies and platform of projects fully focused on the development and implementation of Alternatives for Pharmaceuticals and Biological products, as well as for Cosmetics, Food, Chemicals, etc. For that, it is needed to identify what each Group/National Network is able to contribute with in technical and scientific terms and the funding bodies interested in supporting this initiative in a continent with a low development in the field of 3Rs. Moreover, the collaboration with experienced institutions and organizations devoted to Alternatives from developed countries could provide significant benefits to reach our purposes. The definition of statements, a working structure (including a Board) and an Action Plan will be the priority of this Presentation in order to give the first step toward a near future with more development and implementation of Alternatives in Latin-America.

Citation Format: Chovel ML (2014) WHY AND FOR WHAT CREATING A LATINAMERICAN-IBEROAMERICAN NETWORK FOR ALTERNATIVES? [abstract]. In: Proceedings of the LATINFARMA 2013; 2013 October 21–25; La Habana, Cuba: SCF; J Pharm Pharmacogn Res 2(Suppl. 1): S39.

© 2014 Journal of Pharmacy & Pharmacognosy Research (JPPRes)